Scholarlink

<p>Myeloid/lymphoid neoplasm with PDGFRA rearrangement are a group of haematologic tumors, in which the clonal proliferation of precursor eosinophils leads to persistent eosinophilic hyperplasia, and varying degrees of involvement of the liver, spleen and lymph nodes. While PDGFRA rearrangements are frequently observed in mpn-eo, the co-occurrence of t(15;16)(q14;p13) translocations leading to <i>LUC7L::NUTM1</i> fusion genes has not been previously documented. Here we present a 30-year-old male patient with leukocytosis and generalized lymphadenopathy. Bone marrow cytology revealed eosinophilia with abnormal and atypical granulocytes showing dysplastic cytoplasmic granules. Cytogenetic analysis identified t(15;16)(q14;p13), while RNA sequencing confirmed the novel <i>LUC7L::NUTM1</i> fusion gene and co-detected <i>FIP1L1::PDGFRA</i> fusion gene. The patient achieved stable disease imatinib (100&#xa0;mg/day) treatment. This first report of dual <i>PDGFRA/NUTM1</i> fusions expands the molecular spectrum of MPN-Eo and highlights the therapeutic implications of novel fusion detection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel LUC7L::NUTM1 fusion in PDGFRA-rearranged myeloproliferative neoplasm with eosinophilia: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月12日

查看全文
  • Jing Zhou,
  • Hanbing Yao,
  • Jiarong Ren,
  • Ke Sun,
  • Dongxue Chen,
  • Rui Zhang,
  • Gangfeng Wang

摘要

Myeloid/lymphoid neoplasm with PDGFRA rearrangement are a group of haematologic tumors, in which the clonal proliferation of precursor eosinophils leads to persistent eosinophilic hyperplasia, and varying degrees of involvement of the liver, spleen and lymph nodes. While PDGFRA rearrangements are frequently observed in mpn-eo, the co-occurrence of t(15;16)(q14;p13) translocations leading to LUC7L::NUTM1 fusion genes has not been previously documented. Here we present a 30-year-old male patient with leukocytosis and generalized lymphadenopathy. Bone marrow cytology revealed eosinophilia with abnormal and atypical granulocytes showing dysplastic cytoplasmic granules. Cytogenetic analysis identified t(15;16)(q14;p13), while RNA sequencing confirmed the novel LUC7L::NUTM1 fusion gene and co-detected FIP1L1::PDGFRA fusion gene. The patient achieved stable disease imatinib (100 mg/day) treatment. This first report of dual PDGFRA/NUTM1 fusions expands the molecular spectrum of MPN-Eo and highlights the therapeutic implications of novel fusion detection.